Abstract 12388: Changes of Diastolic Function Following Anthraclycline-based Chemotherapy: A Prospective Study
Background: Chronic Anthracycline cardiotoxicity represents a major limitation for its use in cancer patients (Pts). Data about the incidence and evolution of diastolic dysfunction following anthracycline treatment scarce.
Methods: 105 consecutive pts receiving Anthracycline (A)-based chemotherapy (CHT) (100pts for breast cancer- 5pts for lymphomas) were included in this prospective study. All Pts underwent an echocardiogram and clinical evaluation at baseline, at the end of A CHT, 3 and 9 months after the end of A CHT. Fifteen pts receiving Trastuzumab were monitored with an extra echocardiogram 6 and 12 months after the end of A CHT in order to monitor Trastuzumab toxicity. We recorded pulsed Tissue Doppler imaging at mitral annulus (septal and lateral walls), color M-mode propagation velocity and standard mitral inflow diastolic parameters. Peak velocities in early diastole (E), propagation velocity (Vp) of the mitral inflow as well as standard mitral inflow parameters were measured.
Results: At the end of follow-up (median 12.1 months, interquartile range 11.6-13.3) no pts developed clinical heart failure. Three pts(2.8%) had a mild decrease of ejection fraction (mean EF 50.3%). Fourteen pts(13.3%) had baseline diastolic dysfunction. Fifty-one pts(48%) developed diastolic dysfunction which persisted by the end of follow-up in 37pts(35%). Forty pts(38%) didn’t develop significant diastolic changes. Changes in diastolic parameters are showed in figure 1(* indicates p value<0.05 comparing with basal measurement).
Conclusions: Development of diastolic dysfunction in Anthracycline chemotherapy is common and can be permanent, although it is clinically silent.
- © 2012 by American Heart Association, Inc.